505 - 516 of 7680 results
0.75 CME CREDIT

This talk on deep vein thrombosis (DVT) will review common clinical presentations, diagnostic workup, indications for imaging, and therapeutic options. The consequences of DVT, such as pulmonary embolism and stroke (in patients with patent foramen ovale), can be dire, and the faculty will provide strategies to reduce morbidity and mortality. You will dive into a detailed lesson on the medical therapy for DVT, which includes anticoagulation strategies using warfarin or the novel factor Xa inhibitors. After this session, you will know when to refer for more advanced invasive therapies and have insight into management of special populations. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 9th, 2020, and they are subject to change as new information is published.


1.5 CME CREDITS

Whether we realize it or not, the stories we witness and the narratives we are privileged to co-author give meaning to our work as clinicians. However, stress and burnout prevent many from connecting with these stories. This session will provide the unique perspectives of three different speakers who will discuss storytelling, the “4Rs” (reflection, relationships, resourcefulness, and resilience), and fiscal health. From them, you will learn preemptive approaches for managing stress and promoting resilience as well as strategies to obtain non-medical income streams that could put you in position for a more optimal work-life balance. With these tools, you may find more bandwidth to engage with the stories of your patients and restore satisfaction in your work.


1 CME CREDIT

This lecture will focus on assessment and management of depression and anxiety in primary care. In addition to receiving an overview of screening tools and interview techniques, attendees will learn about challenges and obstacles to treating depression and anxiety. Topics will include recognizing frequent symptom presentations, differential diagnosis, common mistakes in prescribing, and a brief review of new medications. The speaker will discuss a treatment-to-target approach and how to choose medications based on side effect profile and target symptoms. Management of suicidal ideation and deciding when to refer are also highlighted topics for discussion in this session on the urgent need for optimal treatment of depression and anxiety in primary care.


1 CME CREDIT

Stroke can be devastating and lead to significant disability and/or death. Diagnosing and treating stroke symptoms as well as factors associated with transient ischemic attacks—often a stroke warning sign—are of paramount importance. The faculty in this talk will discuss the crucial role of the primary care team in post-stroke care and how you can ensure the best recovery for your patients who have suffered from stroke.


0.75 CME CREDIT

Governor Charlie Baker of Massachusetts will discuss ongoing priorities that build on his administration’s work to strengthen the Commonwealth’s healthcare system, ensure access to quality, affordable healthcare for all, and tackle the opioid epidemic.


1 CME CREDIT

In the U.S., about 15.1 million people have an alcohol use disorder and about 4.8 million misuse opioids. This session focuses on the pharmacotherapy of alcohol and opioid use disorders. The faculty will describe and contrast naltrexone and acamprosate treatments for alcohol use disorder and discuss the use of buprenorphine/naloxone to treat opioid use disorder.


1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.


1 CME CREDIT

Providing safe and effective pain control can be achieved despite the serious public health crisis of the opioid overdose and misuse epidemic currently affecting the United States and other countries. This talk will review the evolution of the present-day opioid epidemic to better understand current risks. Terminology associated with addiction, currently referred to as substance use disorder, will be defined. Assessment of pain is imperative, with a shift away from intensity to functional ability. Risk factors for misuse must also be assessed. These findings inform the treatment regimen, including whether opioids are indicated, and if so, what mitigating strategies must be implicated to reduce the risk of misuse. Techniques such as harm reduction, weaning and safe handling will be addressed.


1 CME CREDIT

This talk will cover recent clinical trials presented at the ADA in 2019 that have an impact on the management of diabetes, such as cardiovascular outcomes trials and the first oral GLP-1 RA phase 3 data. The faculty will take you through the latest guidelines from the ADA regarding the management of type 2 diabetes and describe how recent clinical trial data has been integrated in to these guidelines. After this meeting review, you will be equipped to manage type 2 diabetes based on these guidelines.


1 CME CREDIT

This talk will give a historical perspective of psychiatry and how its course of change has impacted primary care clinicians. Please note that any data, indications, and guidelines presented in this activity are current as of the recording/release on February 7, 2020, and they are subject to change as new information is published.


1 CME CREDIT

Faculty will review the prior data regarding antiplatelet and anticoagulant therapy. He will also present highlights from the recent late breaking clinical trial presentations from the European Society of Cardiology.


1 CME CREDIT

Growth is a fundamental process of childhood that is followed longitudinally by primary care. Poor growth velocity warrants an evaluation to identify an underlying pathology, whether endocrine or non-endocrine, whereas short stature refers to height below the normal spectrum of the population. You will learn more about common pathologies that may present with poor growth and contrast them with genetic mechanisms that contribute to variation in the population. Growth hormone—which was traditionally restricted to use in those with growth hormone deficiency—is the main intervention available to increase final adult height. As it commonly has efficacy to increase stature outside of the setting of growth hormone deficiency, the number of FDA-approved indications for its use have expanded over the past decades. The faculty in this lecture will also discuss considerations by pediatric endocrinologists in the prescription of growth hormone.